Vista Pharmaceuticals Limited (BOM:524711)
India
· Delayed Price · Currency is INR 6.24
+0.15 (2.46%)
At close: Mar 10, 2026
Vista Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Operating Revenue | 86.3 | 100.75 | 102.88 | 10.04 | 3.95 | 12.66 | Upgrade
|
| Other Revenue | - | - | - | - | -0 | - | Upgrade
|
| Revenue | 86.3 | 100.75 | 102.88 | 10.04 | 3.95 | 12.66 | Upgrade
|
| Revenue Growth (YoY) | -13.51% | -2.07% | 924.99% | 154.42% | -68.85% | -94.44% | Upgrade
|
| Cost of Revenue | 81.05 | 85.34 | 92.86 | 28.61 | 3.9 | 8.47 | Upgrade
|
| Gross Profit | 5.25 | 15.41 | 10.02 | -18.57 | 0.05 | 4.2 | Upgrade
|
| Selling, General & Admin | 24.53 | 21.97 | 20.17 | 5.34 | 7.17 | 12.11 | Upgrade
|
| Other Operating Expenses | 64.03 | 32.37 | 21.71 | 14.93 | 4.99 | 9.39 | Upgrade
|
| Operating Expenses | 96.02 | 61.72 | 49.07 | 26.44 | 18.32 | 28.77 | Upgrade
|
| Operating Income | -90.78 | -46.31 | -39.05 | -45.01 | -18.27 | -24.57 | Upgrade
|
| Interest Expense | -7.15 | -9.24 | -12.34 | -13.1 | -8.98 | -15.45 | Upgrade
|
| Interest & Investment Income | 1.75 | 1.75 | 1.45 | 1.29 | 1.66 | 1 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.41 | -0.41 | -0.69 | -1.63 | -0.57 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 2.14 | 1.32 | 1.43 | -0.31 | -0.02 | 0.91 | Upgrade
|
| EBT Excluding Unusual Items | -94.45 | -52.9 | -49.21 | -58.76 | -26.18 | -38.11 | Upgrade
|
| Other Unusual Items | - | - | -2.57 | - | - | - | Upgrade
|
| Pretax Income | -94.45 | -52.9 | -51.77 | -58.76 | -26.18 | -38.11 | Upgrade
|
| Income Tax Expense | -17.51 | -6.41 | -6.65 | -2.14 | -17.29 | -18.03 | Upgrade
|
| Net Income | -76.94 | -46.49 | -45.12 | -56.62 | -8.89 | -20.09 | Upgrade
|
| Net Income to Common | -76.94 | -46.49 | -45.12 | -56.62 | -8.89 | -20.09 | Upgrade
|
| Shares Outstanding (Basic) | 58 | 59 | 44 | 37 | 37 | 35 | Upgrade
|
| Shares Outstanding (Diluted) | 58 | 59 | 44 | 37 | 37 | 35 | Upgrade
|
| Shares Change (YoY) | 5.50% | 34.66% | 18.55% | 0.11% | 6.18% | 14.11% | Upgrade
|
| EPS (Basic) | -1.32 | -0.79 | -1.03 | -1.54 | -0.24 | -0.58 | Upgrade
|
| EPS (Diluted) | -1.32 | -0.79 | -1.03 | -1.54 | -0.24 | -0.58 | Upgrade
|
| Free Cash Flow | - | -74.25 | -57.04 | -29.82 | -10.07 | -70.46 | Upgrade
|
| Free Cash Flow Per Share | - | -1.26 | -1.31 | -0.81 | -0.27 | -2.03 | Upgrade
|
| Gross Margin | 6.08% | 15.29% | 9.74% | -185.00% | 1.22% | 33.14% | Upgrade
|
| Operating Margin | -105.19% | -45.97% | -37.96% | -448.47% | -463.07% | -194.04% | Upgrade
|
| Profit Margin | -89.16% | -46.14% | -43.86% | -564.11% | -225.25% | -158.62% | Upgrade
|
| Free Cash Flow Margin | - | -73.70% | -55.44% | -297.07% | -255.34% | -556.35% | Upgrade
|
| EBITDA | -83.26 | -38.93 | -31.86 | -38.84 | -12.11 | -17.3 | Upgrade
|
| EBITDA Margin | -96.48% | -38.64% | -30.96% | - | - | -136.58% | Upgrade
|
| D&A For EBITDA | 7.52 | 7.38 | 7.2 | 6.18 | 6.16 | 7.28 | Upgrade
|
| EBIT | -90.78 | -46.31 | -39.05 | -45.01 | -18.27 | -24.57 | Upgrade
|
| EBIT Margin | -105.19% | -45.97% | -37.96% | - | - | -194.04% | Upgrade
|
| Revenue as Reported | 91.52 | 105.15 | 106.21 | 14.03 | 5.6 | 14.61 | Upgrade
|
| Advertising Expenses | - | 0.79 | 1.14 | 0.1 | 0.66 | 0.08 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.